Nature Research, Nature Immunology, 7(14), p. 696-697, 2013
DOI: 10.1038/ni.2646
Full text: Download
The glycoprotein CD52 is an important target for clinical antibodies, but its receptor and function have remained a mystery. However, it now seems that CD52 may be released in soluble form by a subpopulation of human T cells and may thereby exert an as-yet-unrecognized regulatory function via the inhibitory molecule Siglec-10.